Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.
Josh J Carlson, Kangho Suh, Panos Orfanos...
https://pubmed.ncbi.nlm.nih.gov/29488070/Actively Recruiting
Led by Instituto Nacional de Cancerologia de Mexico · Updated on 2026-04-08
45
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are studying the pharmacokinetics of alectinib, an oral drug given to Mexican patients with advanced ALK-positive non-small cell lung cancer NSCLC. The study aims to find out the peak blood concentrations of alectinib as the dose increases from 300 mg to 600 mg twice daily over nine weeks. It also evaluates how well patients respond to the treatment and tracks disease progression and side effects over time. In the first phase, patients take alectinib in increasing doses every 21 days, starting at 300 mg twice daily and moving up in 150 mg steps to 600 mg twice daily. Blood samples are collected before and after doses on specific days to measure drug levels. After this phase, patients continue treatment with the dose chosen based on earlier results until their disease worsens or side effects become unacceptable. This phase also measures the overall response rate to the drug. Participants will have regular assessments including blood tests, imaging scans every six weeks to monitor tumor response, and evaluations of side effects and survival. Researchers will measure drug concentration levels, treatment response, progression-free survival, and overall survival throughout the study. The study lasts several months, with close observation during dose escalation and ongoing follow-up during treatment.
CONDITIONS
Alectinib Pharmacokinetic in Patients With NSCLC
O
Oscar G Arrieta Rodriguez, M.D., M.Sc.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Instituto Nacional de Cancerologia de Mexico
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to several months depending on study phase and response
Participants receive Alectinib with sequential dose escalation every 21 days in phase 1 and then an investigator-chosen dose in phase 2 based on pharmacokinetic analysis.
Visits every 21 days for dose escalation and additional visits for pharmacokinetic assessments; CT scans every 6 weeks
Duration - Up to 120 months
Participants are monitored for progression-free survival, overall survival, and adverse events after the end of treatment.
Periodic follow-up visits over several years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Josh J Carlson, Kangho Suh, Panos Orfanos...
https://pubmed.ncbi.nlm.nih.gov/29488070/Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo...
https://pubmed.ncbi.nlm.nih.gov/28501140/Peter N Morcos, Eveline Nueesch, Felix Jaminion...
https://pubmed.ncbi.nlm.nih.gov/29748847/Solange Peters, D Ross Camidge, Alice T Shaw...
https://pubmed.ncbi.nlm.nih.gov/28586279/Marine Sivignon, Rémi Monnier, Bertrand Tehard...
https://pubmed.ncbi.nlm.nih.gov/31945065/Instituto Nacional de Cancerologia de Mexico
Lead Sponsor